Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine

Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was administered to a 74-year-old man with MDS-F...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Okamura, Daisuke, Matsuda, Akira, Ishikawa, Maho, Maeda, Tomoya, Tanae, Ken, Kohri, Mika, Takahashi, Naoki, Kawai, Nobutaka, Asou, Norio, Bessho, Masami
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2014
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4009407/
https://ncbi.nlm.nih.gov/pubmed/24809010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lrr.2014.03.002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars